Stockscreener 앱 받기
9.75
0.62%
0.06
시간 외 거래:
9.75
전일 마감가:
$9.69
열려 있는:
$9.7
하루 거래량:
3.26M
Relative Volume:
1.42
시가총액:
$1.02B
수익:
$64.52M
순이익/손실:
$-95.55M
주가수익비율:
-9.588
EPS:
-1.0169
순현금흐름:
$-84.65M
1주 성능:
+1.46%
1개월 성능:
+53.30%
6개월 성능:
+25.97%
1년 성능:
+56.50%
1일 변동 폭
$9.5172
$10.63
1주일 범위
$9.14
$10.63
52주 변동 폭
$3.84
$12.53
Personalis Inc Stock (PSNL) Company Profile
명칭
Personalis Inc
전화
650-752-1300
주소
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
9.75 | 1.03B | 64.52M | -95.55M | -84.65M | -1.0169 |
TMO
Thermo Fisher Scientific Inc
|
461.69 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.76 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
546.09 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
124.33 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.00 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-15 | 개시 | Guggenheim | Buy |
| 2025-03-17 | 개시 | Craig Hallum | Buy |
| 2023-02-06 | 업그레이드 | Needham | Hold → Buy |
| 2022-01-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | 다운그레이드 | Needham | Buy → Hold |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-20 | 재확인 | Needham | Buy |
| 2021-05-06 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2021-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-12 | 재확인 | Needham | Buy |
| 2020-11-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-08-18 | 개시 | Needham | Buy |
| 2019-09-26 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 개시 | BofA/Merrill | Neutral |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Morgan Stanley | Overweight |
| 2019-07-15 | 개시 | Oppenheimer | Outperform |
모두보기
Personalis Inc 주식(PSNL)의 최신 뉴스
PSNL Q1 2026 Earnings: EPS Misses Estimates, Stock Declines on Weak ResultsRetail Earnings Report - newsline.com
Personalis (NASDAQ: PSNL) director receives 6,250 RSU award in Form 4/A update - Stock Titan
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Lightspeed funds (NASDAQ: PSNL) report 5.8% Personalis stake after in-kind distributions - Stock Titan
Personalis Inc. (PSNL) Q1 2026 Earnings: Loss Wider Than Expected, Stock DipsPost-Announcement Reaction - newsline.com
Personalis blood collection kits receive EU regulatory approval - Investing.com UK
Personalis (PSNL) Receives CE Mark Approval for Blood Collection Kits - GuruFocus
Personalis Gains EU Approval for Blood Collection Kits Used in Genomic Testing - Moomoo
Personalis blood collection kits receive EU regulatory approval By Investing.com - Investing.com Nigeria
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire
Personalis, Inc. Hits Day Low of $10.39 Amid Price Pressure - MarketsMojo
Personalis, Inc. Hits New 52-Week High of $11.84, Up 763.64% - MarketsMojo
Personalis CFO Aaron Tachibana sells $480,400 in company stock - Investing.com UK
Personalis CFO Aaron Tachibana sells $480,400 in company stock By Investing.com - Investing.com Australia
Personalis (NASDAQ: PSNL) CFO sells 40,000 shares under 10b5-1 plan - Stock Titan
Personalis Inc. (PSNL) Q1 2026 Earnings: EPS Misses Estimates Amid Revenue Reporting GapsNegative Surprise Momentum - newsline.com
Aaron L. Tachibana (PSNL) exercises 40,000 options; prior 38,799 10b5-1 sale - Stock Titan
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? - The Globe and Mail
Personalis Inc. (PSNL) Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesEPS Estimate Trend - newsline.com
Personalis Data Highlights Early Cancer Recurrence Detection - Clinical Lab Products
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 - BioSpace
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance
Personalis Insider Sold Shares Worth $449,292, According to a Recent SEC Filing - marketscreener.com
Personalis stock hits 52-week high at $11.51 By Investing.com - Investing.com Australia
Personalis CEO Christopher M. Hall sells $1.1m in stock By Investing.com - Investing.com India
Personalis CEO Christopher M. Hall sells $1.1m in stock - Investing.com
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock By Investing.com - Investing.com Australia
Personalis CFO and COO Aaron Tachibana sells $449,292 in stock - Investing.com
Personalis (NASDAQ: PSNL) CEO sells 100K shares after exercising options - Stock Titan
Personalis (PSNL) CFO sells shares via pre-set Rule 10b5-1 plan - Stock Titan
Personalis (PSNL) Is Up 34.5% After CMS Expands NeXT Personal MRD Test Medicare Coverage - simplywall.st
[144] Personalis, Inc. SEC Filing - Stock Titan
Personalis, Inc. Hits Day High with 15.7% Surge in Stock Price - MarketsMojo
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL) - Seeking Alpha
ETFs Investing in Personalis, Inc. Stocks - TradingView
Personalis gains after fourth Medicare coverage win for NeXT Personal - MSN
Personalis Inc (PSNL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Personalis Inc 주식 (PSNL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tachibana Aaron | CFO AND COO |
Jun 04 '26 |
Sale |
12.01 |
40,000 |
480,400 |
198,833 |
1.63%
2.88%
자본화:
|
볼륨(24시간):